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a  b  s  t  r  a  c  t
A  high  performance  liquid  chromatographic  method  was  developed  for the  simultaneous  deter-
mination  of  the  related  substances  (R-ivabradine,  dehydro-S-ivabradine,  N-demethyl-S-ivabradine,
((S)-3,4-dimethoxy-bicyclo[4.2.0]octa-1,3,5-triene-7-yl-methyl)-methyl-amine)  and  1-(7,8-dimethoxy-
1,3,4,5-tetrahydro-2H-3-benzazepine-2-on-3-yl)-3-chloro-propane)  of the  heart-rate  lowering  drug,
ivabradine.  The  separation  capability  of  seven  different  polysaccharide-type  chiral  columns  (Lux
Amylose-1,  Lux i-Amylose-1,  Lux  Amylose-2,  Lux  Cellulose-1,  Lux  Cellulose-2,  Lux Cellulose-3  and  Lux
Cellulose-4)  was  investigated  with  a mobile  phase  consisting  of  0.1%  diethylamine  in  methanol,  2-
propanol  and acetonitrile.  During  the  screnning  experiments  the  best  results  were  obtained  on  Lux
Cellulose-2  (based  on cellulose  tris(3-chloro-4-methylphenylcarbamate)  column  with  methanol  with
an ideal  case,  where  all the  impurities  eluted  before  the  S-ivabradine  peak.  Chromatographic  parameters
(flow  rate,  temperature  and  mobile  phase  constituents)  were  optimized  by a  full factorial  screen-
ing  design.  Using  optimized  parameters  (Lux Cellulose-2  column  with  0.06%  (v/v) diethylamine  in
methanol/acetonitrile  98/2  (v/v)  with  0.45  mL/min  flow  rate  at 12 ◦C) baseline  separations  were  achieved
between  all  compounds.  The  optimized  method  was  validated  according  to the  International  Council  on
Harmonization  Q2(R1)  guideline  and  proved  to be reliable,  linear,  precise  and accurate  for  determination
of  at least  0.05%  for  all impurities  in S-ivabradine  samples.  Method  application  was  tested  on a commer-
cial  tablet  formulation  and  proved  to be suitable  for routine  quality  control  of both  chiral  and  achiral
related  substances  of  S-ivabradine.
© 2019  The  Authors.  Published  by  Elsevier  B.V.  This  is  an  open  access  article  under  the  CC  BY-NC-ND. Introduction
Ivabradine 3-{3-[((S)-3,4-dimethoxy-bicyclo[4.2.0]octa-1,3,5-
riene-7-ylmethyl)-methyl-amino]-propyl}-7,8-dimethoxy-
,3,4,5-tetrahydro-2H-3-benzazepine-2-one; IVA) is an orally
ioavailable, hyperpolarization-activated, cyclic nucleotide-gated
∗ Corresponding author at: Department of Pharmaceutical Chemistry, Semmel-
eis University, H-1092 Budapest, Hőgyes E. u. 9, Hungary.
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channel inhibitor. It is used for chronic heart failure not fully
managed by -blockers [1,2]. IVA has a single asymmetric carbon
atom, resulting in two  optical isomers. The drug is marketed as
a single enantiomeric agent; the pharmaceutical formulations
contain only the S-enantiomer, because of its improved electro-
physiological selectivity [3,4]. Nevertheless, to date, only one
application note from Daicel Chiral technologies is available for
chiral separation of IVA using Chiralpak IG (based on amylose
tris(3-chloro-5-methylphenylcarbamate) column [5]. Moreover,
the number of the described method for determination of achiral
related substances in IVA is also limited [6–9]. High performance
liquid chromatography (HPLC) using a chiral stationary phase
(CSP) is the golden standard in analytical enantioseparation due to
the several advantages it offers, such as ease of use, robustness and
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ood transferability between laboratories. Today, out of numerous
SPs available on the market, polysaccharide-type CSPs are the
ost frequently applied, due to their high enantiorecognition
apability for most of the compounds and multimodal nature
10–12]. These columns can be operated in normal phase, reversed
hase and polar organic mobile phase modes. In polar organic
ode only polar organic solvents, neat alcohols (methanol, ethanol
nd 2-propanol), neat acetonitrile (ACN) or their combinations are
sed as mobile phase. Polar organic mode has several advantages,
uch as shorter run times, high efficiency, and usually higher solu-
ility of the analytes in the mobile phase [12–15]. Apart from their
bility to discriminate between enantiomers, polysaccharide-type
SPs may  also present excellent chemoselectivity for structurally
elated compounds, therefore they can be used for simultaneous
etermination of chiral and chemical impurities [14,16,17].
All specified impurities, including R-enantiomer are of inter-
st in the analysis of S-IVA. Therefore, the aim of the present
tudy was to develop a method for the simultaneous determination
f R-IVA, dehydro-S-ivabradine (DHIVA), N-demethyl-S-ivabradine
DMIVA), ((S)-3,4-dimethoxy-bicyclo[4.2.0]octa-1,3,5-triene-7-yl-
ethyl)-methyl-amine (IMP-1) and 1-(7,8-dimethoxy-1,3,4,5-
etrahydro-2H-3-benzazepine-2-on-3-yl)-3-chloro-propane (IMP-
) (Fig. 1) in S-IVA samples with a limit of quantification of at least
.05% or below.
. Materials and methods
.1. Materials










-yl)-3-chloro-propane (IMP-2) (Fig. 1) were obtained from a
harmaceutical company in Târgu Mureş . Diethylamine (DEA)
99.5% was purchased from Sigma-Aldrich (Budapest, Hungary).
radient grade methanol (MeOH), 2-propanol (IPA) and acetoni-
rile (ACN) were purchased from Thomasker Finechemicals Ltd.
Budapest, Hungary).
Ultrapure, deionized water was prepared by a Milli-Q Direct
 Millipore system (Milford, MA,  USA). S-IVA 5 mg  film-coated
ablets were obtained from Central Pharmacy of Semmelweis Uni-
ersity (Budapest, Hungary). All chiral columns with identical
imensions (4.6 x 150 mm,  5 m particles) were ordered from Phe-
omenex (Torrance, CA, USA): Lux Cellulose-1 [cellulose tris(3,5-
imethylphenylcarbamate)], Lux Cellulose-2 [cellulose tris(3-
hloro-4-methylphenylcarbamate)], Lux Cellulose-3 [cellulose
ris(4-methylbenzoate)], Lux Cellulose-4 [cellulose tris(4-chloro-
-methylphenylcarbamate)], Lux Amylose-1 [amylose tris(3,5-
imethylphenylcarbamate)], Lux i-Amylose-1 [amylose tris(3,5-
imethylphenylcarbamate)], immobilized and Lux Amylose-2
amylose tris(5-chloro-2-methylphenylcarbamate)] (Supplemen-
ary Information Figure S1).
.2. LC-UV analysisLC-UV experiments was carried out on a JASCO HPLC system
JASCO PU-2089 Plus binary gradient pump, AS-4050 autosampler,
D-2010 Plus diode array detector and CO2065 Plus column oven).utical and Biomedical Analysis 177 (2020) 112851
The software used to operate the equipment and data processing
was ChromNAV. UV detection was performed at 286 nm. MeOH  was
used as a sample solvent for the preparation of solutions through-
out the study. For the preliminary experiments, stock solutions of
200 g/mL S-IVA were prepared in MeOH and were spiked with
impurities at around 2% (around 4 g/mL). The final test solution
of S-IVA used for validation and method applicability testing was
about 8000 g/ml. All impurity level percentages are reported rel-
ative to this concentration. An injection volume of 5 L was used
and three parallel measurements were performed in all cases.
For preparation of sample solutions, ten tablets were weighted,
then ground and mixed in a mortar. In a 5 mL volumetric flask,
MeOH was  added to an accurately weighted portion of the
tablet powder corresponding to about 40 mg  S-IVA. Then the
suspension was  sonicated for 30 min  and centrifuged for 2 min
applying 4000 rpm (Sartorius 2–16 P benchtop centrifuge, Goettin-
gen, Germany). The clear supernatant was  filtered through 0.22 m
pore size syringe containing PVDF filter (FilterBio membrane Co.,
LTD, Nantong City, China).
The experimental design and multivariate method optimiza-
tion was  performed with the aid of Modde 11 software (Umetrics,
Sweden).
3. Results and discussion
3.1. Method scouting phase
In routine quality control of single enantiomeric pharmaceutical
substances, the “classical approach” would be to develop separate
methods for the quantification of achiral and chiral related sub-
stances. Methods that enable simultaneous quantification of both
chiral and achiral impurities are thus highly welcome, because
they can significantly shorten the analysis time. However, in these
cases, the developed methods need to display both enantioselec-
tivity (chiral separation) and chemoselectivity (achiral separation)
towards the analytes. Although this can also be achieved by tandem
coupling of chiral and achiral columns, using a single chiral column
is more desirable. Thus, for the present method, based on regula-
tory considerations, the analytical target profile was defined as a
method that would allow the precise and accurate determination
of all selected impurities (chiral and chemical) at a level of at least
0.05% or below, in short analysis time (t ≤ 30 min).
Recently, we  have successfully applied polysaccharide-based
CSPs in polar organic mode for the chiral separation of a large vari-
ety of analytes [18–21], however polysaccharide-type CSPs have
also proved their capability for simultaneous chiral-achiral analy-
ses [14,16,17].
Polysaccharide-based CSPs come in a wide variety of commer-
cially available columns and usually display a great variety of
enantio- and chemoselectivity. In the present study, seven different
polysaccharide-based CSPs, including amylose-based Lux Amylose-
1, Lux i-Amylose-1 and Lux Amylose-2, as well as cellulose-based
Lux Cellulose-1, Lux Cellulose-2, Lux Cellulose-3 and Lux Cellulose-
4 were tested in polar organic mode using a mobile phase consisting
of 0.1% DEA in MeOH, IPA or ACN, with 0.5 mL/min flow rate at
25 ◦. In our screening the combination of polar organic solvents
was not used, however it should be noted that solvent mixture can
change the enantiorecognition mechanism and also can improve
the resolution.
During the screening step in all cases, IMP-1 and IMP-2 were
well resolved from each other and the main peak, however, dif-
ficulties were observed during the separation of the structurally
very similar DHIVA, DMIVA, R-IVA from the main peak for which
co-elutions were often observed. Particularly challenging was the
resolution of IVA enantiomers, which was identified as the critical
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Fig. 1. Name, chemical structure and abbreviations of the compounds used in this study.
Table 1
Summary of the chromatographic data obtained during the preliminary screening phase.
Column Mobile phase* Rs Enantiomer elution
order
tr, min Last eluted compound
Lux Amylose-1
MeOH 0.25 R < S 23.1 S-IVA
IPA 1.34 R < S 16.1 S-IVA
ACN 0.24 S < R 19.0 DMIVA
Lux  i-Amylose-1
MeOH – – 11.2 IVA
IPA  0.86 R < S 20.3 S-IVA
ACN  – – 10.8 IVA
Lux  Amylose-2
MeOH 1.06 S < R 18.2 R-IVA
IPA – – 49.3 DMIVA
ACN  1.80 S < R 49.9 DMIVA
Lux  Cellulose-1
MeOH 2.15 S < R 10.6 R-IVA
IPA 1.64 S < R 19.6 DMIVA
ACN  2.60 S < R 8.9 DMIVA
Lux  Cellulose-2
MeOH 1.78 R < S 19.9 S-IVA
IPA – – 40.9 DMIVA
ACN  0.20 R < S 39.3 DMIVA
Lux  Cellulose-3
MeOH 2.73 S < R 9.3 R-IVA
IPA – – 11.7 DMIVA
ACN  – – 5.0 DMIVA
Lux  Cellulose-4
MeOH 0.25 R < S 14.1 S-IVA
IPA – – 35.8 DMIVA
ACN  1.11 R < S 26.4 DMIVA







r, retention time of the last eluted peak.
 all mobile phases contained 0.1% DEA as basic modifier.
 no enantiorecognition could be observed.arameter. Thus, the screening was focused mainly on selecting the
dequate column for baseline separation of the enantiomers with
he desired elution order (chiral impurity and R-IVA eluting beforethe eutomer). Some of the chromatograms obtained are depicted
in Fig. 2, while the relevant chromatographic data are presented in
Table 1. As it can be observed, baseline chiral separation between































ig. 2. Representative chromatograms obtained during the preliminary study. Chro
ith  0.1% DEA in MeOH; (C) Lux Cellulose-2 with 0.1% DEA in ACN; (D) Lux Cellu
86  nm.) 1. IMP-1, 2. IMP-2, 3. DHIVA, 4. DMIVA, 5. R-IVA, 6. S-IVA.
nantiomers was achieved on the Lux Cellulose-1 column with
igh resolution values for all three mobile phases, but the elution
rder of the enantiomers was unfavorable. Distomer-first elution
rder was observed on Lux-i-Amylose-1, Lux Cellulose-2 and Lux
ellulose-4, but the baseline separation was achieved only in the
ase of Lux Cellulose-2 using 0.1% DEA in MeOH as mobile phase.
obile phase dependent enantiomer elution order was  recorded
n Lux Amylose-1 column, when changing the main component of
he mobile phase from alcohols to ACN.
Since the final goal was to develop a single method for the
eparation of all related substances, not only enantioselectiv-
ty, but chemoselectivity was also important. Thus, for further
ethod optimization the following starting-point was selected:
ux Cellulose-2 column, with 0.1% DEA in MeOH with 0.5 mL/min
ow rate at 25 ◦C. By applying this method, all investigated related
ubstances could be resolved. Moreover, not only the enantiomeric
mpurity R-IVA, but all investigated impurities eluted before S-
VA (Fig. 2A). In an attempt to gain higher resolution MeOH was
hanged to EtOH, however using the ethanolic mobile phase DMIVA
nd S-IVA co-eluted, therefore it was not suitable (Supplementary
nformation Figure S2). Addition of small amounts of ACN to MEOH
s a secondary solvent, however, lead to reduced retention times
ithout modifying the resolutions significantly (Supplementary
nformation Figure S3). Thus, this option was also evaluated during
urther method optimization.
.2. Method optimization by experimental designConventional method optimization is usually performed by the
o-called OFAT approach (one factor at a time), which leads to
 multitude of experiments, whilst gaining only little knowledgeraphic conditions: (A) Lux Cellulose-2 with 0.1% DEA in MeOH; (B) Lux Cellulose-3
 with 0.1% DEA in MeOH (flow rate: 0.5 mL/min, temperature 25 ◦C, detection at
about the process itself. Due to these shortcomings, experimental
design-based, multivariate optimization of analytical techniques
have become widespread in recent years. The main advantage of
this approach is that it offers maximum process understanding with
a minimal number of experiments [22,23].
Thus, a multivariate methodology was undertaken for a rapid
optimization of numerous parameters affecting the simultaneous
separation of the analytes. Based on the preliminary experimental
runs, four critical quality attributes were selected and monitored
as responses in the experimental runs. These included: Rs between
DHIVA and DMIVA (abbreviated Rs1), Rs between DMIVA and R-
IVA (Rs2), Rs between R-IVA and S-IVA (Rs3) and total analysis
time (measured as retention time of S-IVA, tr,S-IVA). Critical process
parameters were identified based on our previous experience with
polar organic mode on polysaccharide-type CSPs and a risk assess-
ment of different factors that could influence the performance of
the method. The critical process parameters selected as experimen-
tal variables during the DoE runs were defined as DEA volume ratio
added to the mobile phase (DEA%, range 0.05% – 0.15%), ACN/MeOH
volume ratio of the mobile phase (ACN%, 0–10%), flow rate (0.3 –
0.7 mL/min) and column temperature (T, 10–40 ◦C). In our work
DEA was  used as modifier however the nature of the basic and/or
acidic modifier may  deeply influence the separation [15].
In order to obtain thorough information about the influence of
defined factors on selected responses and thereby to achieve the
optimal chromatographic conditions, aiming to fulfil all response
target settings, a full factorial experimental design with three cen-
ter points was selected.
The design returned a total of 19 experimental runs, including
three replicate center pointed experiments. The sample consisted
of 8000 g/mL S-IVA and 80 g/mL of each impurity (impurity
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Table  2
Optimized method conditions with predicted and experimentally obtained response values.
Optimized method conditions Rs1 Rs2 Rs3 tr,S -IVA
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evels at 1.0% relative to S-IVA) in MeOH. All experimental runs
ere performed in triplicate and the average values were intro-
uced in the worksheet. The design matrix and the recorded values
or all responses are summarized in Supplementary Information
able S1. The obtained data was fitted by partial least squares (PLS)
egression and the model passed the replicative plot analysis for all
esponses (Supplementary Information Figure S4), meaning that
eplicate errors did not interfere with data analysis. Histogram
lots of responses indicated normal distribution for reponses Rs1,
s3, but not for Rs2 and tr,S-IVA. For the latter two, the histograms
howed strong positive skewness, implying that the frequency of
ower values in the dataset was much higher. In order to achieve
pproximately normal distribution, logarithmic transformations
ere employed, which resulted in a substantial increase in model
redictability (Q2) for both responses. The model was further
djusted by deleting non-significant factors and adding detected
quare values to increase the Q2 values. The final coefficient plots
btained, with the significant factors affecting each response are
resented in Supplementary Information Figure S4. For all of mon-
tored responses, the experimental variables ACN%, flow rate and
 presented a negative correlation, indicating that an increase in
ny of these factors resulted in a decrease in all Rs values, but also
 decrease in tr,S-IVA. DEA% in most cases had no significant effect
pon the responses, apart from Rs2 where, in comparison to ACN%,
ow rate and T also presents a significant inverse proportionality
ith the selected response, although being the least influential of
he defined factors.
Further model refinement implied the appraisal of quadratic
erms inside the model. The presence of quadratic terms indicates a
on-linear relationship in-between factors and responses and sug-
ests the existence of curvature inside the model. Quadratic terms
ere not identified in case of Rs2 and Rs3. Regarding Rs1 and tr , S-IVA
ignificant quadratic terms were observed and included in the anal-
sis of model performance indicators. As the refined model allows
nly one quadratic term to be included in the regression equation,
his was fulfilled by selecting the one for which the corresponding
ingular factor has the greatest impact on the selected response.
ence, in case of Rs1 and tr , S-IVA, ACN% x ACN% and Flow x Flow
ere retained, respectively.
In all cases, significant regression models were obtained (p <
.05) and apart from the case of tr,S-IVA, no lack of fit was  detected
p > 0.05). In the latter case, the lack of fit was also evident by
he negative model validity value. In contrast to this, model repro-
ucibility showed extremely high values (0̃.99), since the replicate
uns resulted in almost identical retention times of the main peak
see Supplementary Information Table S1). Although retention time
eproducibility is desirable and mostly expected in chromato-
raphic techniques, this also means, that the pure error inside the
odel tends to zero and thus, the low model validity in case of
r , S-IVA can be explained by high reproducibility. The method was
ubsequently optimized using the prediction spreadsheet function
f the software, applying the following criteria: all Rs values maxi-
ized, with a critical minimal value ≤ 1.5, and tr,S-IVA minimized.
The optimizer set point results obtained after the performed
xperiments during screening is based on a Monte Carlo simu-
ation, where parameter settings were chosen according to thelues
lowest log(D) value, with DEA = 0.058%, ACN = 1.68%, flow rate
=0.46 mL/min and column temperature = 12.0 ◦C. Design space was
evaluated around the aforementioned parameter settings. The 4D
design space explorer map  (Supplementary Information Figure S5)
indicates that the chromatographic system returns optimal results
only at low column temperature and flow rate settings. At the low-
est set points of both the flow rate and column temperature, the
proportion of ACN is allowed to be used in a wider range, showing a
shift towards tighter specification limits as higher settings for both
flow rate and column temperature are required. The set point analy-
sis function of the software revealed that the frequency histograms
of the selected factors and defined responses follow a normal dis-
tribution (Supplementary Information Figure S6 and S7), and the
individual probability of failure for the defined responses is situ-
ated below 1%, with an overall probability of failure of 1.7%. For ease
of use, the final proposed method uses slightly different parame-
ter settings (most parameter settings are rounded), which still lie
inside the design space and return satisfactory results in terms
of selected response requirements. Table 2 shows the optimized
parameters of the chromatographic system and the closeness of
the predicted and experimentally obtained values for all responses,
using the recommended settings. Since the analytical target profile
of the method was fulfilled, further method optimization was not
undertaken. The parameters of the final method were the follow-
ing Lux Cellulose-2 column with 0.06% (v/v) DEA in MeOH/ACN 98/2
(v/v) with 0.45 mL/min flow rate at 12 ◦C.
3.3. Method validation and application
Validation of the optimized method was performed according
to International Council for Harmonization guideline Q2 (R1) for all
related substances and for R-IVA as chiral impurity, with respect
of sensitivity, linearity, accuracy, and precision [24]. The limit of
detection (LOD) and the limit of quantification (LOQ) were cal-
culated based on signal-to-noise ratios of 3:1 and 10:1 for the
LOD and LOQ, respectively. (Baseline noise was  measured con-
sidering a peak to peak within 3 min  selected in three different
parts of the chromatogram of the standard solution.) The obtained
values are summarized in Table 3. Based on the results, the lin-
earity of the method was  evaluated at eight concentration levels
for all impurities and calibration plots were represented by plot-
ting peak areas against corresponding concentrations (expressed
in g/mL). The correlation coefficient was determined by linear
least squares regression analysis and it is higher than 0.9972 in all
cases. Moreover, for all impurities 95% confidence intervals of the
y-intercepts included zero and random distribution of the residuals
was observed.
The accuracy and precision were analyzed by performing intra-
(repeatability) and inter-day evaluation (two consecutive days) of
three concentration levels for all impurities, covering the linear-
ity range, each solution being injected five times. The accuracy
(expressed in mean recovery%) ranged from 97.52% to 104.32%. The
repeatability (expressed as RSD%) determined by five parallel injec-
tions of the solutions on the same day was  between 0.41% and 2.29%.
Intermediate precision of the method (expressed in RSD%) was
investigated on two consecutive days and was lower than 3.56%.
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Table  3
Assay validation data.













r2 0.9992 0.9989 0.9980 0.9997 0.9972
LOD  (g/mL) 0.12 0.12 0.81 0.60 1.20
LOQ  (g/mL) 0.40 0.40 2.70 2.0 4.0
Accuracy (%)
I* 98.90 ± 0.90 104.32 ± 1.01 99.69 ± 1.03 103.92 ± 1.45 103.45 ± 1.19
II** 97.52 ± 1.12 99.55 ± 2.21 102.65 ± 0.99 97.91 ± 0.75 98.94 ± 0.67
III*** 98.29 ± 0.22 101.81 ± 0.88 103.51 ± 0.75 99.81 ± 0.19 98.62 ± 0.34
Content
repeatability (RSD)
I* 1.95 1.53 2.29 1.50 0.63
II** 0.68 0.55 1.19 1.02 0.97
III*** 0.41 0.56 0.55 0.49 0.66
Content precision
(RSD)
I* 2.12 1.74 3.56 1.69 1.11
II** 0.69 0.38 1.26 1.09 1.01
III*** 0.82 0.49 0.81 1.52 2.27
* Level I: IMP-1 = 4 g/ml, IMP-2 = 4 g/ml, DHIVA = 4 g/ml, DMIVA = 5.4 g/ml, R-IVA = 8 g/ml.
** Level II: IMP-1 = 16 g/ml, IMP-2 = 16 g/ml, DHIVA = 12 g/ml, DMIVA = 10.8 g/ml, 
*** Level III: IMP-1 = 56 g/ml, IMP-2 = 56 g/ml, DHIVA = 40 g/ml, DMIVA = 54 g/ml, R
Fig. 3. Chromatograms of (A) Solution of Ivabradine 5 mg  tablet. (B) Solution
of  Ivabradine 5 mg  film-coated tablet spiked with all impurities at the 0.05%

















(SHIFT): a randomised placebo-controlled study, Lancet 376 (2010) 875–885,eOH/ACN 98/2 (v/v) with 0.45 mL/min flow rate at 12 ◦C. 1. IMP-1, 2. IMP-2, 3.
HIVA, 4. DMIVA, 5. R-IVA, 6. S-IVA.
Based on the obtained results the optimized method proved to
e sensitive, linear, accurate and precise for the determination of
ve different impurities, including R-IVA as chiral impurity.
The optimized and validated method was applied to the analysis
f real samples, in the form of film-coated tablets with a nomi-
al content of 5 mg  S-IVA base. The representative chromatograms
ecorded for the sample solution and the sample solution spiked
ith impurities are shown in Fig. 3A and B, respectively. Only R-IVA
f the monitored impurities could be quantified in the commercial
ablet, the other impurities were below (or close) the LOD. The con-
ent of R-IVA was 0.032 ± 0.001%. In addition to the known related
ubstances, minor unidentified peaks could also be observed in the
ample chromatogram, which could be indicating unknown impu-
ities or may  be the results of different exicipients used in the tablet
ormulation. Using peak normalization at 286 nm, the sum of the
otal impurities was calculated as 0.14 ± 0.01%.R-IVA = 16 g/ml.
-IVA = 56 g/ml.
4. Concluding remarks
A novel, single HPLC method using Lux Cellulose-2 column in
polar organic mode was developed using DoE for the simultane-
ous determination of DHIVA, DMIVA, IMP-1 and IMP-2 as related
substances as well as R-IVA as enantiomeric impurity in S-IVA.
The method was validated according to the International Coun-
cil for Harmonization guideline Q2(R1) and proved to be precise
and accurate for determination of at least 0.05% or below for all
impurities in S-IVA samples. Application of the method was tested
on a commercial tablet and showed that the tablet contains R-
IVA impurity, but below 0.05%. Our method could be applied in an
industrial environment for simultaneous quantification of chemi-
cal and chiral related substances of S-IVA in one run to save time
and money. Furthermore, the present method is another example
that related substances and enantiomeric impurities can be deter-
mined by a single method using polysaccharide-type CSP in polar
organic mode.
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